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Abstract
Sickle cell disease (SCD) is caused by a genetic defect that results in abnormal
hemoglobin genes that can cause devastating health effects like chronic hemolytic anemia and
vaso-occlusive crises. Additionally, sickle cell disease can cause defects in the immune system,
leaving those with the disease highly susceptible to a variety of different infections. In the
pediatric population specifically, the complications of sickle cell disease contribute significantly
to the under-five mortality rate of Nigeria. In response to the Millennium Development Goals 4,
5 and 6, as well as with growing national concern over the challenges faced by sickle cell disease
there was a collaboration with the Federal Ministry of Health (FMOH) with the Millennium
Development Goal office to create a national standard of care for sickle cell disease treatment.
This document was created and published on November 28, 2014, and since then there has not
been a study done to determine if the national guidelines that were created have been adopted or
if there were barriers preventing this from occurring.
The purpose of this study was to seek out health providers in Nigeria from different parts
of the country, with different clinic and provider demographics to examine what current practices
are being used and how they compare with the guidelines. The study aimed to provide a better
understanding of providers awareness of the national guidelines for treatment, what the
proportion of their patients had treatment that followed the guidelines, if their prescription habits
aligned with the guidelines and if not, what the barriers to following the national guidelines
were.
To investigate how provider practices compared to the national guideline for SCD, a
comprehensive online survey was distributed to 96 Nigerian healthcare providers at the joint 14th
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Triennial Congress of Union of National African Paediatric Societies and Associations
(UNAPSA) and the 49th Paediatric Association of Nigeria (PAN) Annual General Meeting and
Scientific Conference in Abuja, Nigeria from January 24-26, 2018. Of the 96 participants that
were contacted, 31 fully completed the survey with a response rate of 32.3%. Important to note
was that the majority of the providers, 58.1%, were not aware that there was a national guideline
for sickle cell disease treatment available. The results of the study show that while specific
treatment practices like malarial prophylaxis and folic acid supplementation are widely used,
there is still much room for improvement for newborn screening, pneumococcal vaccination and
hydroxyurea. In addition to the elements of the national guidelines, there was also interest in the
role of other medications like ciklavit and herbal preparations when it came to sickle cell disease
for which there was little provider support. This study will provide the foundation for future
interventions to increase the awareness and provider knowledge of the national guidelines for
pediatric sickle cell disease treatment to provide better streamlined and universal care for those
affected by this disease in Nigeria.

1. Introduction
Sickle cell disease (SCD) is the result of a genetic mutation that is one of the leading
causes of disease in the world, with some of the highest rates of prevalence being in Nigeria,
where it remains a leading killer of children under five years old (Galadanci 2014). Sickle cell
disease is categorized as a chronic hemolytic disorder. As a result of the mutation, there is a
change in the shape of the red blood cells and they take on a deformed or sickle shape. This
sickle shape causes many different complications in the health of patients leading to vasoocclusive events, pain crisis and hemolysis (Galadanci 2014). According to Adewoyin in the
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Management of Sickle Cell Disease: A Review for Physician Education in Nigeria, “Sickle cell
disease affects about 2 to 3% of the Nigerian population of more than 160 million” (Adewoyin
2015). The majority of patients that have sickle cell disease are not aware of their status, until
they experience a complication from the disease and end up in a general clinic or hospital
(Adewoyin, 2015). This highlights the importance of understanding what the treatment habits are
of not only those who are in specialized sickle cell disease clinics, but also those who are
practicing in the ER, general clinics and hospital settings.
Given the medical complications that can occur with sickle cell disease patients who
develop bacterial infections, malaria and HIV infection, the management and care of sickle cell
disease can be very complicated. It is important to note that while the heterozygote form of the
sickle cell trait can afford some protection against malaria, the homozygous states like that seen
in sickle cell disease can make the effects of malarial infection more severe (Galadanci 2014).
Some of the advised methods of management include ruling out malarial infection, folic acid
supplements, monitoring and caring for anemic states and using antibiotics efficiently when
appropriate. By understanding health care decision making, the disease burden of sickle cell
disease in Nigeria can be improved through better care. An evaluation of healthcare practices
surrounding sickle cell disease in Nigeria was done in a study by Galadanci; in which they
surveyed various sickle cell specific institutions throughout the country to gather data on the
protocol for patients with sickle cell, including diagnosis and treatment (Galadanci, 2014). They
found that it was standard to give folic acid and malaria prophylaxis but that there was a gap in
care for penicillin prophylaxis and pneumococcal vaccines are not routinely provided.
Diagnostically, the study showed that none of the 11 institutions that participated had any
established newborn screening program. The foundation of this study was an important step
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towards establishing better sickle cell management through the 2010 Nigerian SCD Network
who conducted this study to get data on current care and develop a better plan for future care.
In order to face the growing burden of pediatric sickle cell disease on the under-five
mortality, Nigeria passed a national guideline for treatment practices in November of 2014 titled
the National Guideline for the Control and Management of Sickle Cell Disease. This document
provides a foundation for sickle cell screening, treatment and complication prevention (Nigeria
2014). However, no comparison of medical professional treatment of sickle cell disease has
been done since the passage of this national guideline.
By having a standardized treatment plan, there could be better response and treatment of
kids with sickle cell disease. The purpose of this study is to understand what current healthcare
provider knowledge is of the national guidelines and how provider treatment practices compare
to the standard of care described in the national guidelines. Additionally, there was a desire to
understand if there was a gap between the standard and actual current healthcare practice to
identify what the barriers to care were and why certain practices were not always being carried
out. Since the guidelines were created, a study to see the impacts on current practice has not been
done and the results will be important in determining next steps to creating better knowledge and
standardized rules of practice to improve the health of pediatric sickle cell disease patients. This
project will help to understand what current treatment plans are being used, the factors that are
impacting these choices and ways that better care can be provided by understanding the current
barriers. Additionally, this study extends beyond sickle cell specific clinics to include the full
range of health care facilities available. By understanding these gaps in care and why they exist,
we can have specific areas to focus on to create successful interventions to hopefully lead to
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universal standards of care that are also lived out in actual practice to reduce the under-five
mortality due to sickle cell disease.
2. Methods
2.1 Study Design
The design of the study was a questionnaire based on convenience sampling of
health care professionals. The study was conducted in partnership with the International
Foundation Against Infectious Disease in Nigeria (IFAIN). IFAIN has the mission of reducing
and better understanding infectious disease burdens in Nigeria. IFAIN is a Nigerian non-profit,
non-governmental organization that is an affiliate of UNMC. IFAIN was established in 2012
with support from UNMC to manage UNMC research projects in Nigeria.
2.2 Study Population
Medical professionals in Nigeria that work in a pediatric setting were the
participants targeted for this study. The study sample resulted from emails that were collected at
the joint 14th Triennial Congress of Union of National African Paediatric Societies and
Associations (UNAPSA) and the 49th Paediatric Association of Nigeria (PAN) Annual General
Meeting and Scientific Conference in Abuja, Nigeria from January 24-26, 2018. Additionally,
providers through medical clinics in Nigeria that have existing collaborations with IFAIN
participated. Of the 96 total participants that were contacted, there was a 32.3% response rate
with 31 fully completing the survey.
2.3 Data Collection Methods
The survey was completed through the online REDcap system to keep the
information secure and only available to those designated at IFAIN and UNMC. The survey had
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a total of 58 questions that took around 15 minutes to complete, a copy of the detailed questions
can be found in Appendix A. The question types included direct yes/no, multiple choice,
multiple check boxes and fill in the blank responses. The survey was divided into the following
sections; Clinic Characteristics, Provider Demographics, Guideline Knowledge, Provider
Treatment Practices and Furthering Education. This was done in an attempt to understand the
multiple factors that are involved in knowing about and practicing according to the
recommendations set out in the national guidelines. Once the survey was completed by the
participants, they were compensated for the data usage required to participate. Minutes were
added back onto the device that was used to complete the survey by an IFAIN representative in
Nigeria who received the phone numbers through the secure REDcap database
2.4 Data Analysis
Descriptive statistics were used to compare the treatment habits medical
professionals in Nigeria to treatment prophylaxis recommended in the national guidelines. The
analysis provided information regarding knowledge of national guidelines and provider
prescription habits related to the prophylactic measures outlined in the national guidelines for
pediatric sickle cell disease patients. The survey compared results between pediatricians, general
practice physicians, pediatric residents, pediatric subspecialists that are not hematologists and
medical officers. Nurses and community health workers were not participants of this study. The
sites that providers worked in included the hospital, general clinic, ER and specialty clinics. The
primary population demographics, public or private and rural or urban as institution types of the
healthcare providers was also explored. For the questions regarding the proportion of patients on
specific prophylactic treatments the following categories were used, 0-25%, 26-50%, 52-75%
and 76-100%. There were some cases where there were extremes in data with either very few
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patients on treatments or almost all of the patients on treatments and the categories were then
divided up accordingly, i.e. <10% as a category or 90-100% as a category. The results of the
survey can be used to identify gaps between actual healthcare practices and the national
guidelines to aid in policy analysis and interventions to increase the efficiency and uniformity of
treatment of sickle cell disease.
3. Results
There were 96 surveys distributed with 32 surveys submitted and 31 fully
completed survey responses with participants representing various different clinical and
provider demographics with a response rate of 32.3%. The survey was divided into the five
question sections that the results will follow accordingly; Section I: Clinic Characteristics,
Section II: Provider Demographics, Section III: Guideline Knowledge, Section IV: Treatment
Practices, Section V: Furthering Education.
3.1 Section I: Clinic Characteristics
In this section, the purpose was to gather information to describe the different types of
facilities and clinic backgrounds that our providers were working in. This information could then
be used to understand if there was a difference in practice that was related to the clinic
characteristics. The results of the survey found that of the 31 participants, 20 (63.5%) primarily
practiced in a teaching hospital, 3 (9.7%) worked in a hospital inpatient unit, 3 (9.7%) in hospital
outpatient, 2(6.5%) in an emergency room setting, 1(3.2%) in a general clinic and 2 (6.5%) in
other settings. The other settings that were described were a general hospital and a federal
medical center.
When it came to the characteristics of the clinic, providers could choose more than one
option; 2 worked in an adult facility, 13 in a pediatric facility and 17 in an adult and pediatric
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clinic. There were 13 providers that marked that they worked in a public facility and 2 that
worked in a private facility. The majority of providers worked in an institution that was urban, 28
(90.3%) while 3 (9.7%) were from a rural facility. All of the institutions kept medical records,
and of those 17 (54.8%) of them kept a database of their sickle cell disease patients.
The diagnostic equipment for sickle cell disease varied depending on the clinic. Of the
equipment available at the facility participants selected all the options that they had available at
their facility, all had x-ray available, 50% had a transcranial doppler, 60% had a CT and 26.7%
had an MRI machine. For the diagnosis of sickle cell disease in particular, the main method
providers stated that of the diagnostic methods used 87.1% of their facilities used electrophoresis
(cellulose acetate, citrate agar), 9.7% used capillary electrophoresis, 9.7% used HPLC and 3.2%
not being sure. The majority, 23 (74.2%), of providers stated that the facilities did not have a
genetic counselor available at the institution, with only 3 (9.7%) reporting they did and 5
(16.1%) not knowing. Lastly, given the emphasis of newborn screening in the national
guidelines, we were curious to know if newborn screening was done at their facility and found
that 27 (87.1%) do not conduct newborn screening, 3 (9.7%) do and 3 (3.2%) did not know.

3.2. Section II: Provider Demographics
In this section, we wanted to understand the different types of providers that were completing
the survey and gather information on their respective backgrounds to see if this influenced their
knowledge of national guidelines for treatment and their treatment practices. Of those who
completed the survey, 17 (54.8%) were male and 14 (45.2%) were female. There was a range of
ages 31-55 represented with the mean age of providers being 44 with a standard deviation of
6.68. The range of practice years was 5-31 years with an average years of practice of 18.9 years

Health Professional Treatment Practices for Pediatric Sickle Cell Disease in Nigeria

10

with a standard deviation of 7.53 . The education levels of the survey participants showed that 17
held an MBBS, 18 were postgraduate fellows, 3 an MD and 5 had a Master’s degree, with some
providers holding multiple degrees. There were graduates from various institutions including 7
from the National Postgraduate Medical College of Nigeria (NPMNC), 3 from West African
College of Physicians, 17 from African Universities and 3 from International Universities. The
providers were from different areas of Nigeria including Kano, Kwara, Oto, FCT/Abuja and
Lagos.
Professionally, 22 (71%) of the survey participants were identified as pediatricians, 3 (9.7%)
as a pediatric resident/registrar, 3 (9.7%) as a pediatric subspecialist not hematologist and 3
(9.7%) as a medical officer. The participants saw range of pediatric sickle cell disease patients
from 0-40 per week with an average 8.63 pediatric sickle cell patients per week and a standard
deviation of 10.99.
3.3 Section III: Guideline Knowledge
To assess the awareness and use of the national guidelines for sickle cell disease treatment,
we asked the participants about the extent of their guideline knowledge. We found that 15
(48.4%) of the participants had heard about a Nigerian National Guideline for Sickle Cell
Disease Treatment. However, when asked about the National Guideline for the Control and
Management of Sickle Cell Disease (2014), 18 (58.1%) had not heard of the national guideline.
When questioned about the frequency that participants followed the national guidelines for sickle
cell disease treatment, the majority 14 (45.1%) did not know how often they followed the
guidelines, 9 (29%) did often, 3 (9.7%) never did, 2 (6.5%) sometimes did, 1 (3.2%) always did,
1 (3.2%) rarely did and 1(3.2%) did not answer. In order to determine possible barriers to
following the national guidelines in practice, participants were asked to check possible reasons
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for not always following the guidelines. The most commonly identified barriers were asked in a
check all that apply format with the following checked “I did not know that there were national
guidelines” 11 (47.8%), “I do not have a copy of the guidelines” 8 (34.8%) and “I am not the
primary SCD patient provider” 5 (21.7%). Also indicated as barriers, were preference for other
guidelines 2 (8.75%), vaccines not being available 2 (8.7%), labs not being available 1 (4.3%)
and not having received sickle cell disease patient care specific training 1 (4.3%).

3.4 Section IV: Treatment Practices
The core of the practices that were focused on in the survey were the prophylactic measures
recommended by the national guidelines including penicillin prophylaxis, malarial prophylaxis,
pneumococcal vaccination, folic acid supplementation and hydroxyurea. In an attempt to gather
information on other treatment practices, ciklavit and herbal preparations were also included in
this survey. The most widely followed treatment practices were the use of malarial prophylaxis
and folic acid supplementation. There was some use of penicillin prophylaxis and pneumococcal
vaccination, a wide range of practices for hydroxyurea and little use of ciklavit or knowledge of
herbal preparations.
Each subsection can be divided into the following for each treatment practice as the questions
were asked in terms of patient population, frequency of provider prescriptions and a qualitative
assessment of why a practice was not “always” done. For penicillin prophylaxis, 14 of the
respondents estimated that <10% of their patient population was taking penicillin prophylaxis,
followed by 9 that did know, 1 that estimated 11-25%, 1 that estimated 51-75%, 2 that estimated
76-100% and 1 that did not answer. When asked about their prescribing habits for penicillin
prophylaxis, 7 (22.5%) never did, 6 (19.4%) sometimes, 6 (19.4%) rarely did, 5 (16.1%) often
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did, 4 (12.9%) always did and 3 (9.7%) did not answer. When asked why they did not always
prescribe penicillin prophylaxis for their pediatric sickle cell disease patients there were 17
responses, the majority stated that it was not a part of the routine practice/treatment protocol 4
(23.5%), there was not enough evidence for the success of this treatment practice 3 (17.6%), they
referred out their SCD patients 3 (17.6%), the pneumococcal vaccine had already been given 1
(5.9%) or that they did not know that they needed to 1 (5.9%).
For malarial prophylaxis, 24 of respondents estimated that 76-100% of their pediatric sickle
cell disease patients were taking malarial prophylaxis, 1 estimated that 11-25% of their patients
were, 3 estimated 51-75% of their patients were, 1 did not know and 2 did not answer. When
asked about their prescribing habits for malarial prophylaxis, 27 (87.1%) always did, 1 (3.2%)
often, 1 (3.2%) sometimes did and 2 (6.5%) did not answer. For the pneumococcal vaccine, 14
did not know how much of their patient population had received the vaccine, 4 estimated <10%,
4 estimated 51-75%, 3 estimated 11-25%, 3 estimated 26-50% and 2 estimated 76-100%. When
asked about their prescribing habits for the pneumococcal vaccine, 9 (29.0%) always did, 6
(19.3%) sometimes did, 5 (16.1%) often did, 3 (9.7%) never did, 3 (9.7%) rarely did, 2 (6.5%)
said it was unavailable and 3 (9.7%) did not answer. Of those who did not answer that they
always prescribed the pneumococcal vaccine for their pediatric sickle cell disease patients there
were 15 responses, the majority 9 (60%) indicated cost as a major barrier, 3 (20%) stated that
their patients were already immunized, 1 (6.7%) said that the vaccine was unavailable, 1 (6.7%)
that they referred their SCD patients elsewhere and 1(6.7%) answered other.
For folic acid supplementation, 26 respondents estimated that 91-100% of their pediatric
sickle cell disease patients were taking folic acid supplementation, 2 estimated 70-90%, 1 did not
know and 2 did not answer. All of the providers, 100%, said that they always prescribe it. For
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hydroxyurea, the majority of respondents (11) estimated that <10% of their patients were taking
it, 10 did not know, 5 estimated 26-50%, 2 estimated 11-25%, 1 estimated 51-75%, 1 estimated
76-100% and 1 did not answer. When asked about their prescribing habits for hydroxyurea, 8
(25.8%) sometimes did, 6 (19.3%) often did, 6 (19.3%) rarely did, 4 (12.9%) never did, 4
(12.9%) found it unavailable and 3 (9.7%) did not answer. When asked why they did not always
prescribe hydroxyurea for their patients there were 20 responses, the majority of respondents
cited the prescription guidelines based on disease severity 11 (55.0%), referral to a specialist 4
(20%), cost as a barrier 3 (15%) and 2 (10%) stated other.

Figure 1: Graphs Depicting Provider Prescription Habits for SCD Complication Prophylaxis
from Survey Sample of Nigerian Healthcare Providers, 2018 (Respondents N=31)

While not part of the national guidelines, in an attempt to learn about additional provider
habits for pediatric sickle cell disease patients we asked about the proportion of patients taking
Ciklavit. The majority of participants (15) estimated that <10% of their patients were taking
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Ciklavit, 10 did not know, 2 estimated 11-25% and 1 estimated 51-75%. When asked about their
prescribing habits of Ciklavit, 13 (41.9%) never did, 6 (19.3%) rarely did, 3 (9.7%) sometimes
did, 3 (9.7%) found it unavailable, 1 (3.2%) always did and 5 (16.1%) did not answer. When
asked why they did not always prescribe Ciklavit there were 20 responses, 8 (40%) of
respondents were either unfamiliar with Ciklavit or unsure of its efficacy, 5 (25%) found the cost
too high or the medication unavailable, 3 (15%) stated that it was not part of their protocol, 3
(15%) referred out to a specialist and 1 (5%) listed other. Lastly, when asked about herbal
preparations for patients, 22 did not know if their patients were taking home remedies or herbal
treatments, 2 estimated <10%, 1 estimated 11-25%, 1 estimated 26-50%, 1 estimated 51-75%
and 4 did not answer. When asked to specify what their pediatric SCD patients were taking if
they were taking herbal treatments, participants stated a leaf or herb mix was being used or that
they did not know.

3.5 Section V: Furthering Education
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When asked about interest in continuing education on sickle cell disease, 30 (96.8%) of
participants said yes. When asked to check all the preferred method of education the top 3 were
that 23 (74.2%) preferred E-learning modules, 21 (67.7%) online courses and 15 (48.4%) live
educational sessions.

4. Discussion
Nigeria has the highest burden of sickle cell disease in the world, with an annual infant death
rate of about 100,000 or 8% of all infant mortality in the country (Nigeria 2014). The burden of
this disease has far reaching effects and there needs to be a more coordinated effort to
standardize detection, diagnosis, prevention and treatment of sickle cell disease, especially in the
under-five population. In an attempt to streamline care and offer a protocol for how to approach
the prevention, diagnosis and treatment of sickle cell disease, the Nigerian government created
the National Guideline for the Control and Management of Sickle Cell Disease in 2014. Since
the creation of this guideline, there has not been a study to determine if the information that was
meant to be used to provide a universal standard of care has been implemented into daily
practice. In this study, we were able to gather information from various health providers across
Nigeria on the awareness of the current practices outlined in the national guidelines, current
treatment practices and determine possible barriers to care.
The national guideline is comprehensive and serves as a source for facing a variety of
different issues related to sickle cell disease including management of acute complications,
sickle cell disease and pregnancy, etc. We chose to focus our line of questioning on the routine
prophylactic measures that are outlined in the national guidelines. For the purposes of
prevention, we wanted to know what the clinic capabilities were to correctly diagnose sickle cell
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disease patients to know when prophylactic treatment should be initiated. Prevention was also at
the root of questions regarding clinical medical records and sickle cell disease databases to see
the continuity of care in those who have sickle cell disease. The role of genetic counselors and
newborn screening are also used in the national guidelines as key points for prevention of disease
and/or initiation of prophylactic measures to prevent life threatening complications of sickle cell
disease.
The core of the prophylactic measures center around malarial prophylaxis, prevention of
anemia through folic acid supplementation, prevention of infections through penicillin
prophylaxis and the addition of pneumococcal vaccinations to the immunization schedule.
Additionally, hydroxyurea is cited as a prophylactic measure when indicated. While not listed in
the national guidelines, we added the use of Ciklvait and knowledge of home remedies to gain a
more holistic few of possible provider practices. Although our sample size is a small
representation of the whole of the health providers in Nigeria, we were still able to determine
some valuable gaps between the goals of the standard of care outlined in the national guideline
and the actual practice that pediatric sickle cell patients are receiving.
The clinics that the participants work in were mostly public, urban teaching hospitals serving
either pediatric specific or adult and pediatric patients. First, in a discussion of the different
clinics that were represented in our participants, there was a range of different diagnostic
methods that were available and that were most commonly used. In order to know if a patient
requires specific treatment and prophylaxis for sickle cell disease, the disease status of the
patient needs to be known. There national guidelines outline the availability and use of a sickling
test, solubility test, hemoglobin electrophoresis, blood film, high performance liquid
chromatography (HPLC) and isoelectric focusing (IEF) as possible diagnostic tools suitable for
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sickle cell disease. When asked to mark all of the diagnostic options available at their facility, we
found that 30 of the institutions had electrophoresis (cellulose acetate, citrate agar), 3 marked
capillary electrophoresis, 9 marked HPLC and 1 marked IEF. The methods of diagnosis that
were marked were 27 marking electrophoresis (cellulose acetate, citrate agar), 3 marked capillary
electrophoresis, 3 marked HPLC and 1 marked that they did not know.
When it came to record keeping, all of the facilities were determined to medical records with
roughly half of those keeping a database of sickle cell disease patients. Despite the
encouragement for the use of genetic counselors in the national guidelines to aid in education
about sickle cell disease and its route of inheritance, the majority of institutions did not have a
genetic counselor available. Perhaps the most concerning, is that despite the strong push for
newborn screening from a national level, 87.1% of the respondents indicated that newborn
screening is not done at their facility. There might be some confounding variables since we did
not gather information from OB-GYN specific centers, but pediatricians account for a large
number of newborn screenings, especially for those who serve patients that may have been born
at home. Newborn screening can aid in early detection and early prophylaxis or treatment to help
decrease the rate of those who die from early complications of the disease.
In an effort to better understand the background of the study participants, there was a section
specific to the provider demographics. The resulting information showed that most of the
providers were pediatricians holding an MBBS degree, training as a fellow or an MD. When
asked about their patient population, most of the respondents saw up to 10 pediatric sickle cell
disease patients per week. Given the prevalence of the disease in the country and the lack of
surveillance and newborn screening examinations, it was important to open up the survey to
participants that were not just pediatric sickle cell disease specific providers. Since the disease is
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so common, it is not just those who are specifically trained in pediatric sickle cell disease that
need to be aware of the national guidelines and prophylactic measures, but all healthcare
providers need the knowledge to know how to identify those patients with sickle cell disease,
correctly diagnose and provide prophylactic care.
When it came to the knowledge of the national guidelines, there seemed to be a disconnect
between the goals of the guidelines to influence provider practice and the dissemination of the
guidelines so that they could be used. The national guidelines were published in November of
2014 and yet in March of 2018, almost four years later, half of the respondents had not heard of
any set of national guidelines and 58.1% had not heard of the National Guideline for the Control
and Management of Sickle Cell Disease (2014) in particular. This is a huge gap in awareness and
something needs to be done to better disseminate this information throughout the Nigerian
medical community, otherwise a standardized method of care cannot be accomplished. Given the
lack of knowledge about the existence of the national guidelines, it is not surprising that the
majority of the participants did not know if they were following them in their treatment of
pediatric sickle cell disease patients. When questioned about why the national guidelines were
not always followed, the reasons were most commonly cited as not knowing about the
guidelines, not having a copy of the guidelines and not being the primary SCD provider. It was
interesting to note, that of those providers who were pediatricians specifically, 12 were not aware
of the national guidelines and 10 were aware. Given the focus of this study on pediatric sickle
cell disease healthcare, the pediatricians responses were used to cross tabulate information
between other types of providers and their knowledge of the national guidelines.
Despite the majority of providers not being aware of or using the national guidelines as their
primary influence on pediatric sickle cell disease care, there were still some elements of practice
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that fell into line with the goals of the standardized care outlined in the guidelines. For example,
the areas of highest patient population treatment percentage and provider prescribing frequency
were malarial prophylaxis and folic acid supplementation. Given the high rates of death due to
complications of malaria and anemia in sickle cell disease patients, this is encouraging data.
However, given the complications of disease brought on by infection, it was surprising to
see that penicillin prophylaxis and pneumococcal vaccination was still not always routinely seen
in patients or prescribed. In the case of penicillin prophylaxis the most common themes that
arose for not always prescribing penicillin prophylaxis for pediatric sickle cell disease treatment
was that it was not a part of the institutions routine treatment protocol or that there was not
enough evidence that the use of penicillin prophylaxis was helpful. For pneumococcal
vaccinations, the most commonly cited reasons for not prescribing this for their pediatric sickle
cell disease patients was due to concerns about cost or children already being immunized. Given
that both penicillin prophylaxis and pneumococcal vaccinations are outlined as prophylactic
measures in the national guidelines, more information and awareness about their role in
preventing infection and complications needs to be conveyed.
Hydroxyurea treatment was another interesting difference between the standard of care
outlined in the national guidelines and the responses from this survey. Given the different
requirements to determine the need for hydroxyurea treatment depending on disease severity,
there could have been some confusion when asked about prescription habits in a general
pediatric sickle cell disease population. We found that 35.5% thought that <10% of patients were
taking hydroxyurea, however 32.3% did not know. Given that hydroxyurea could have different
implications on treatment and disease state, the amount of providers that did not know if their
patients were taking this was concerning.
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Lastly, we were curious to learn about the proportion of the patient population that was
taking treatments that were not outlined in the national guidelines, but are used in actual practice.
In the case of ciklavit, about half of the providers estimated <10% of their patients were taking
ciklavit, but again there were 32.3% who did not know. When asked about their prescribing
habits of ciklavit about half responded that they never prescribe it, while the others did
sometimes or rarely. The cost and unfamiliarity with its treatment efficacy were cited as reasons
for not always using it. Lastly, in an effort to better understand home remedies and herbal
treatments, we wanted to know how many patients were taking these and what they were using if
they were. Again, almost 71% of the respondents did not know and of those who did they
weren’t sure what the treatment was aside from it being a leaf or herb mix.
In concluding the study, there was a great interest in wanting to learn more about sickle
cell disease through a variety of different online and in person educational methods. This lines up
well with the recommended changes and implementations that could take place to better
disseminate the information that is provided in the national guidelines. While there is still a long
way to go for the standardized treatment of pediatric sickle cell disease in Nigeria to decrease the
burden of disease and under-five mortality, health providers are willing and interested to improve
treatment practices and patient care.
The limitations of this study largely fall on access to internet for survey completion
since many medical professionals in Nigeria rely on the use of data on personal devices to access
the internet. Another limitation could be bias due to convenience sampling. With the bulk of
recruiting being done at the joint 14th Triennial Congress of Union of National African Paediatric
Societies and Associations (UNAPSA) and the 49th Paediatric Association of Nigeria (PAN)
Annual General Meeting and Scientific Conference in Abuja, Nigeria, that could target an
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audience that is personally invested in being kept up to date on the most recent and wellestablished treatment options. Due to the technology availability and success of the online
survey formation, there was a smaller respondent size than hoped for that could be difficult to
form conclusions from. However, there was still a response rate of over 30% and while overt
generalizations cannot be made, trends were still obtained and recommendations can be created.
The results will help provide a foundation to guide future research projects.

5. Conclusion
While the sample size of this study is small and not representative of all the healthcare
providers in Nigera, there are still some important conclusions that can be reached. The first goal
of the study was to evaluate current provider awareness and knowledge of the National Guideline
for the Control and Management of Sickle Cell Disease of 2014. The results of those who
participated in this study showed that about half of the providers were not aware of the
guidelines. Of the healthcare providers in this survey, 18 (58.1%) had not heard of the national
guidelines, leading to the conclusion that there is a gap in the national standard and current
practice if the majority of providers are not aware of what the national standard of care is. Given
that this was a core healthcare push by the Nigerian government to standardize care and reduce
the rate of under 5 child mortality, there is more that needs to be done. In an effort to increase the
awareness of these guidelines and adherence to the recommended healthcare protocol there needs
to be a better dissemination of information. Given the prevalence of the disease, these
recommendations should be incorporated into medical training and daily practice.
The next major conclusion is there needs to be a more coordinated effort to implement
prevention strategies for the complications of pediatric sickle cell disease. The two most
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important steps for this would be a universal newborn screening program and the use of genetic
counselors. Both of these are recommendations in the national guidelines, but that showed low
utilization among the institutions of the study participants. The use of these would provide the
basis for earlier detection and prophylactic measures to reduce the rates of preventable mortality.
In terms of prophylactic treatment, malarial prophylaxis and folic acid supplementation showed
good utilization among all the participants. However, infection prevention with the penicillin
prophylaxis, pneumococcal vaccination and hydroxyurea were still inconsistent and not
standardized. Other treatment practices like ciklavit and herbal medications were largely either
unused or used without direct provider knowledge.
Lastly, there was high participant interest in furthering their sickle cell disease knowledge
and a desire to learn more. This provides hope for the future and for those who have sickle cell
disease in Nigeria. While the current rates of pediatric sickle cell disease and associated under-5
mortality are still high, there is growing awareness and interest in medical providers to combat
this disease burden. With the creation of the National Guideline for the Control and Management
of Sickle Cell Disease, the goal for care is set and the providers want to improve care. In order
for these guidelines to be implemented and the providers to follow these standards, there needs to
be work done to bridge the gap and to make this information more accessible and utilized
throughout the country. Important steps have been taken, but only when the protocol moves to
implementation can we hope to see the necessary changes for Nigeria optimally manage its
pediatric sickle cell disease burden.
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6. Reflection
In concluding this project there were a number of important points to reflect on. First,
was the realization of all the work that goes into conducting research. I have never been
involved in the research aspect of public health and medicine before, so this was a very eyeopening experience. There is so much careful planning and prep work that occurs even
before the initiation of the project that was interesting to learn about and to be a part of. The
second realization that I had was the vast opportunities available in the realm of global
health. I had committee members that were physicians, researchers and public health
specialists and each person plays an integral role in the field of global health as a whole. As a
student with the hopes of going into global health, this was encouraging and exciting. Lastly,
I realized how much I am capable of as an MD/MPH student. This was the first time that I
have been able to apply my knowledge and my passions in a substantial way that can help
contribute to the field of work that I have always wanted to be a part of.
The global health community at UNMC is far reaching and is doing amazing and
innovative world to help make it a better place for all. I think that being able to complete my
MPH and to have worked collaboratively with people that are doing these amazing things to
complete a project that may serve to help others is very fulfilling. I know that the experiences
that I have had throughout this process have helped to shape my perspective and my
understanding of the public health world, which will also ultimately play a large role in who I
become as a physician. There is still much work to be done in both the field of medicine and
public health in both local and international contexts, but I feel equipped and excited about
the part that I might play to help those who are in need.
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